197 related articles for article (PubMed ID: 29297039)
1. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs.
Ablavsky G; Larrimore Ouellette L
JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039
[No Abstract] [Full Text] [Related]
2. A Method for Approximating Future Entry of Generic Drugs.
Beall RF; Darrow JJ; Kesselheim AS
Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781
[TBL] [Abstract][Full Text] [Related]
3. A "Method of Use" to Prevent Generic and Biosimilar Market Entry.
Tu SS; Sarpatwari A
N Engl J Med; 2023 Feb; 388(6):483-485. PubMed ID: 36734878
[No Abstract] [Full Text] [Related]
4. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
Wang B; Liu J; Kesselheim AS
JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
[No Abstract] [Full Text] [Related]
5. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
Hong SH; Shepherd MD; Scoones D; Wan TT
J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
[TBL] [Abstract][Full Text] [Related]
6. Using a drug-safety tool to prevent competition.
Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
[No Abstract] [Full Text] [Related]
7. Market exclusivity for top-selling pharmaceuticals: too long, too short, or just right?
Downing NS
JAMA Intern Med; 2015 Apr; 175(4):637-8. PubMed ID: 25664529
[No Abstract] [Full Text] [Related]
8. [Discount for only one drug of the same group leads to impaired health care quality].
Bergström R
Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
[No Abstract] [Full Text] [Related]
9. Strategies That Delay Market Entry of Generic Drugs.
Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
[TBL] [Abstract][Full Text] [Related]
10. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
11. Skies darken over drug companies.
Holmes D
Lancet; 2012 May; 379(9829):1863-4. PubMed ID: 22616103
[No Abstract] [Full Text] [Related]
12. A shift on "pay for delay"--reopening doors for pharmaceutical competition?
Hemphill Kraus EJ
N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478
[No Abstract] [Full Text] [Related]
13. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
14. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
[TBL] [Abstract][Full Text] [Related]
15. Pricing increases for cancer drugs sparks investigation.
Venkatesan P
Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
[No Abstract] [Full Text] [Related]
16. European Court of Justice.
Baeyens A
Eur J Health Law; 2020 May; 27(2):180-186. PubMed ID: 33652402
[No Abstract] [Full Text] [Related]
17. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
18. Delaying generic competition--corporate payoffs and the future of Plavix.
Shuchman M
N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
[No Abstract] [Full Text] [Related]
19. Competition in prescription drug markets: the roles of trademarks, advertising, and generic names.
Feldman R; Lobo F
Eur J Health Econ; 2013 Aug; 14(4):667-75. PubMed ID: 22815099
[TBL] [Abstract][Full Text] [Related]
20. Addressing Generic-Drug Market Failures - The Case for Establishing a Nonprofit Manufacturer.
Liljenquist D; Bai G; Anderson GF
N Engl J Med; 2018 May; 378(20):1857-1859. PubMed ID: 29768140
[No Abstract] [Full Text] [Related]
[Next] [New Search]
